Atomoxetine for attention deficit hyperactivity disorder in mental retardation

Pediatric Neurology

Volumn 43, Issue 5, 2010, Pages 341-347

  Fernández Jaén, Alberto ^a   Fernández Mayoralas, Daniel Martín ^a   Calleja Pérez, Beatriz ^a   Muñoz Jareño, Nuria ^b   Del Rosario Campos Díaz, María ^c  

^a Hospital Universitario Quiron   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c Psicoaula Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; IRRITABILITY; MALE; MENTAL DEFICIENCY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PROPYLAMINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 77957736472     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2010.06.003     Document Type: Article

References (30)

1. B.L. Handen, and R. Gilchrist Practitioner review: Psychopharmacology in children and adolescents with mental retardation J Child Psychol Psychiatry 47 2006 871 882
2. N.N. Singh, C.R. Ellis, and H. Wechsler Psychopharmacoepidemiology of mental retardation: 1966 to 1995 J Child Adolesc Psychopharmacol 7 1997 255 266
3. A. Fernandez-Jaen Attention deficit hyperactivity disorder and mental retardation [Trastorno por déficit de atención e hiperactividad y retraso mental] [In Spanish] Rev Neurol 42 Suppl 2 2006 S25 S27
4. D. Shaffer, P. Fisher, and M.K. Dulcan The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study J Am Acad Child Adolesc Psychiatry 35 1996 865 877
5. P. Strømme, and T.H. Diseth Prevalence of psychiatric diagnoses in children with mental retardation: data from a population-based study Dev Med Child Neurol 42 2000 266 270
6. E. Emerson Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability J Intellect Disabil Res 47 2003 51 58
7. L.E. Arnold, M.G. Aman, and A.M. Cook Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial J Am Acad Child Adolesc Psychiatry 45 2006 1196 1205
8. M.G. Aman Stimulant drugs in the developmental disabilities revisited J Dev Phys Disabil 12 1996 347 365
9. M.G. Aman, R.A. Kern, P. Osborne, R. Tumuluru, J. Rojahn, and V. del Medico Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects Am J Ment Retard 101 1997 521 534 (Pubitemid 27164295)
10. M.G. Aman, B. Buican, and L.E. Arnold Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies J Child Adolesc Psychopharmacol 13 2003 29 40
11. B.L. Handen, J. Janosky, S. McAuliffe, A.M. Breaux, and H. Feldman Prediction of response to methylphenidate among children with ADHD and mental retardation J Am Acad Child Adolesc Psychiatry 33 1994 1185 1193
12. D.A. Pearson, C.W. Santos, and C.D. Casat Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD J Am Acad Child Adolesc Psychiatry 42 2003 209 216
13. M.G. Aman, K.S. Lam, and M.E. Van Bourgondien Medication patterns in patients with autism: temporal, regional, and demographic influences J Child Adolesc Psychopharmacol 15 2005 116 126
14. M.G. Aman, A. Collier-Crespin, and R.L. Lindsay Pharmacotherapy of disorders in mental retardation Eur Child Adolesc Psychiatry 9 Suppl 1 2000 S98 107
15. L.L. Greenhill, J.M. Swanson, and B. Vitiello Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial J Am Acad Child Adolesc Psychiatry 40 2001 180 187
16. P.W. Troost, M.P. Steenhuis, and H.G. Tuynman-Qua Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study J Child Adolesc Psychopharmacol 16 2006 611 619
17. B. Vaughan, J. Fegert, and C.J. Kratochvil Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder Expert Opin Pharmacother 10 2009 669 676
18. F. Montañés-Rada, A.B. Gangoso-Fermoso, and M.A. Martínez-Granero Drugs for attention deficit hyperactivity disorder [Fármacos para el trastorno por déficit de atención/ hiperactividad] [In Spanish] Rev Neurol 48 2009 469 481
19. D.J. Posey, R.E. Wiegand, J. Wilkerson, M. Maynard, K.A. Stigler, and C.J. McDougle Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders J Child Adolesc Psychopharmacol 16 2006 599 610
20. R.J. Jou, B.L. Handen, and A.Y. Hardan Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders J Child Adolesc Psychopharmacol 15 2005 325 330
21. D. Michelson, D. Faries, J. Wernicke Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo controlled, dose-response study Pediatrics 108 2001 E83(1-9)
22. D. Michelson, A.J. Allen, and J. Busner Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 159 2002 1896 1901
23. Research Units on Pediatric Psychopharmacology [RUPP] Autism Network A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity Arch Gen Psychiatry 62 2005 1266 1274
24. C.S. Tang, W.J. Chou, and A.T. Cheng Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation J Child Adolesc Psychopharmacol 19 2009 319 320
25. D.K. Kelsey, C.R. Sumner, and C.D. Casat Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial Pediatrics 114 1 2004 e1 e8
26. J. Biederman, and S.V. Faraone Attention-deficit hyperactivity disorder [Erratum in: Lancet 2006;367:210] Lancet 366 2005 237 248
27. M. Steele, P.S. Jensen, and D.M. Quinn Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28 2006 1892 1908
28. A. Fernández-Jaén, D.M. Fernández-Mayoralas, A. Pardos, B. Calleja-Pérez, and N. Muñoz-Jareño Clinical and cognitive response to extended-release methylphenidate (Medikinet®) in attention deficit/hyperactivity disorder: efficacy evaluation Adv Ther 2010 Jan 16 [Epub ahead of print]
29. S. Prasad, and C. Steer Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence Paediatr Drugs 10 2008 39 47
30. A. Pardos, A. Fernández-Jaén, and D. Martín Fernández-Mayoralas Social skills in attention deficit hyperactivity disorder [Habilidades sociales en el trastorno por déficit de atención/hiperactividad] [In Spanish] Rev Neurol 48 2009 S107 S111